ABOUT THE PROJECT
Metastatic bladder cancer is a lethal and under-studied disease. Chemotherapy has historically been the most effective treatment for advanced bladder cancer, but long-term survival with this metastatic disease has been a rarity. Recently, new drugs including immunotherapies are showing significant promise, but only a certain portion of patients respond to these treatments. Currently we have no reliable way of predicting who the positive responders will be.
The study aims to determine whether the isolation of tumor DNA from a blood test might be a useful way identify changes in tumor DNA (known as mutations) that correspond to treatment response or resistance. Results from this research could lead to a relatively simple and minimally-invasive test to better predict those patients who may respond to immunotherapy. Dr. Wyatt’s team also expects to reveal the landscape of so-called clinically-actionable mutations that are present in metastatic bladder cancer; a finding that will help accelerate the clinical development of novel “precision medicine” based treatment options for patients with this disease.